Exact Sciences Corp (EXAS) reports robust financial performance and raises full-year guidance, driven by strong screening ...
Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback